Financial Performance - The company expects a net profit attributable to shareholders in the range of 1,040,000 to 1,100,000 CNY, representing an increase of 116.22% to 128.70% compared to the previous year's profit of 480,981.9 CNY[4] - The company has achieved a historical high in operating performance by effectively managing challenges such as the pandemic, inflation, and rising raw material costs[6] - Investment income attributable to the company has increased year-on-year, along with foreign exchange gains due to the appreciation of the US dollar, contributing positively to overall performance[6] Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the annual report[2][7] - The performance forecast period covers January 1, 2022, to December 31, 2022[3] - The board of directors assures the accuracy and completeness of the announcement content, taking legal responsibility for any misstatements[2] Strategic Planning - The company has focused on strategic planning and operational goals to mitigate adverse factors impacting performance[5] - The company emphasizes cost reduction and efficiency improvement to enhance product gross margins and ensure profitability[6] - The company has maintained stable production capacity and secured raw material supply to support market sales[6] Investor Advisory - Investors are advised to exercise caution and consider investment risks based on the preliminary nature of the financial forecast[7]
颖泰生物(833819) - 2022 Q4 - 年度业绩预告